Compare American Electric Power Company Inc (AEP) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? American Electric Power Company Inc trades at $123.83 (market cap $67.28B), while Alnylam Pharmaceuticals, Inc. trades at $224.22 (market cap $29.60B). The key difference: American Electric Power Company Inc is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and American Electric Power Company Inc pays a 3.07% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| AEP | ALNY | |
|---|---|---|
Market Cap | $67.28B | $29.60B |
Sector | Utilities | Health |
52-Week High | $138.69 | $491.22 |
52-Week Low | $106.44 | $205.48 |
Enterprise Value | $120.17B | $27.56B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $122.84, down 2.3% on the day, with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, supported by 69 GW of contracted load and a $78 billion capital plan. Analyst consensus remains strongly bullish with a $140.89 price target and no sell ratings.
The outlook is positive due to robust demand from data centers and infrastructure growth, but risks include high capital expenditures and interest expenses. Valuation metrics like a P/E of 21.42 are elevated, requiring sustained earnings growth to justify. The stock offers a stable dividend, with the next payment of $0.95 ex-dividend on August 10, 2026.
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
